Caribou Biosciences, Inc. (Nasdaq: CRBU), a prominent clinical-stage biopharmaceutical company focused on CRISPR genome editing, has announced a webcast scheduled for 8:00 AM ET on Monday, November 3, 2025. The event will provide updates on new data from two significant clinical trials.
During the webcast, the company plans to share findings from the ANTLER phase 1 clinical trial, which assesses vispacabtagene regedleucel (vispa-cel; previously known as CB-010). This allogeneic anti-CD19 CAR-T cell therapy is being evaluated for its effectiveness in treating patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
Additionally, the webcast will present the first clinical data from the CaMMouflage Phase 1 clinical trial, which investigates CB-011, an allogeneic anti-BCMA CAR-T cell therapy, aimed at patients with relapsed or refractory multiple myeloma.
The company will also outline its proposed design for a pivotal phase 3 trial for vispa-cel and discuss the next steps in the ongoing clinical development of CB-011.
Individuals interested in the presentation can access a live webcast through the Events page on Caribou”s official website. An archived version of the webcast will be available on the website for 30 days following the event.
